Skip to content

Legend Biotech

US · LEGN #2374 by market cap Listed 2020
15.25 -0.85 -5.28%
Periodic snapshot; not a real-time feed. · 2026-11-20 20:02

Price chart

Pre-market 15.93 -1.06%
After-hours 15.44 +1.25%
Overnight 15.93 -1.06%
36.2815.2515.252026-05-262026-11-20
MA5MA10MA20MA60
— MA5 — MA10 — MA20 — MA60
Reader sentiment Are you bullish or bearish on LEGN?

Anonymous reader poll. Unscientific, not investment advice.

✦ StockVane Quant Insights how this is computed

Quant Sentiment Neutral
  • Recent price momentum is -36.4% on average (3-month/1-year).
  • Main-fund capital flow has been a net outflow over the last 45 sessions.
  • Short interest has fallen to 6.1% of float.
  • Analyst tilt is Buy.
Quant Technical Outlook Neutral
  • Price is below its 20-day average and below its 60-day average.
  • The 20-day average is above the 60-day average, a short-term uptrend.
Quant Rating, last 30 days E → E

Computed by a StockVane algorithm from historical price, valuation and analyst data - not a person, not a forecast guarantee, and not investment advice.

Factor grades

Ranked against 2848 U.S. stocks StockVane covers.

Last computed: 2026-11-21 20:27 UTC

Data coverage: 5 of 6 factors. Missing data is not a zero score.

Overall D-

The radar needs all six factors. Available grades are shown below.

Valuation C

How expensive the stock is versus earnings, sales and its own 5-year history.

Forward P/E 26.5x Better than 22%
Price / Sales 2.5x Better than 49%
Growth N/A

How fast revenue, profit and free cash flow are compounding.

Not enough data to grade this factor.

Profitability C-

How much profit the business keeps from each dollar of sales and capital.

Gross margin 60.3% Better than 75%
Operating margin -13.3% Better than 14%
Net margin -28.8% Better than 11%
Return on equity -29.1% Better than 13%
Return on invested capital -22.1% Better than 12%
Momentum D-

Recent price strength, skipping the latest month to avoid short-term noise.

3-month return -30.1% Better than 18%
6-month return -48.1% Better than 8%
12-month return (ex latest month) -32.9% Better than 7%
Distance below 52-week high 59.3% Better than 11%
Financial Health C

Balance-sheet strength: leverage, liquidity and interest coverage.

Current ratio 2.0x Better than 55%
Debt to assets 23.9% Better than 50%
Interest coverage -12.2x Better than 12%
Analyst View B+

What the Street thinks: share of Buy ratings and upside to the average target.

Analysts rating Buy 60.0% Better than 36%
Upside to average target 174.8% Better than 93%

Grades are relative rankings, not forecasts: A+ is the top 5% of the covered stocks on a factor, F the bottom 3%. Valuation is not adjusted for sector. Background recomputation is scheduled every 6 hours; actual computation time is shown above, and source datasets have different reporting dates. Not investment advice or tailored to your financial situation.

Performance

1W -12.86%
1M -19.78%
3M -28.27%
6M -45.77%
YTD -29.85%
1Y -44.61%
3Y -74.79%
5Y -72.40%

Key statistics

Price & volume

Prev close
16.10
Open
15.95
Day range
15.15 - 16.13
Avg price
15.48
Volume
3.42M
Turnover
52.99M
Amplitude
6.12%
52-week range
15.15 - 37.50

Valuation

P/E
-9.41
P/E (TTM)
-762.50
P/B
2.33
EPS
-1.62
Net profit
-314.23M
Net assets
1.27B

Share structure

Market cap
2.96B
Float cap
1.39B
Shares out
193.97M
Float shares
91.01M

Dividend & listing

Dividend (TTM)
0.00
Listing date
2020-06-05
52-week range 0% of range
15.15 37.50

59.3% below the 52-week high

Trading activity

Net capital flow main funds, last 45 sessions

-21.05M net over the window

Short interest

Shares short
11.90M
As of
2026-10-30

Frequently asked questions

What is the current stock price of Legend Biotech (LEGN)?

Legend Biotech last traded at 15.25. This page shows a periodic quote snapshot. Check the displayed quote time.

What is Legend Biotech's market cap?

About 2.96B.

What is the P/E ratio of Legend Biotech?

The trailing twelve-month P/E is -762.50. The Valuation tab shows it against the stock's own five-year range.

Does Legend Biotech pay a dividend?

Legend Biotech does not currently pay a regular dividend.

Is Legend Biotech a buy according to analysts?

The consensus of 10 analysts is a Buy rating, with an average 12-month price target of 41.90, which implies 174.8% upside from the current price. This is not investment advice.

What is Legend Biotech's StockVane Quant Rating?

The StockVane Momentum strategy currently rates Legend Biotech a E (Strong Sell). Below its 200-day average and near the bottom of the universe on momentum. Not investment advice.

Quote time 2026-11-20 20:02:40 · For reference only, not investment advice and not tailored to your situation.

Legend Biotech discussion 0 comments

Add a comment